Anand Mehra
QuietNamed in filings at Sofinnova Venture Partners
- Board seats filed
- 6
Named in filings at Sofinnova Venture Partners
all filings on record
last 24 months
from a verified or cited source
| Amplyx Pharmaceuticals | Biotech & pharma | July 2017 | NEA, Rivervest |
| Merus N.V. | Biotech & pharma | January 2017 | Vivo Innovation |
| AERIE PHARMACEUTICALS | Biotech & pharma | September 2014 | None on file |
| Aclaris Therapeutics | Biotech & pharma | September 2014 | Aisling Capital, Vivo Innovation |
| Spark Therapeutics | Biotech & pharma | May 2014 | None on file |
| First Aid Beverages | Biotech & pharma | February 2013 | Healthquest Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Anand Mehra on the board, based on 6 filed seats with a verified or cited source.